Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22932193 | 1.00 | EPHX2 (0.37) | EPHX2JAK2CYP3A4JAK1JAK3 | |
| SCHEMBL22931767 | 0.92 | EPHX2 (0.37) | EPHX2JAK2CYP3A4JAK1JAK3 | |
| SCHEMBL22932203 | 0.86 | DHODH (0.40) | EPHX2CYP3A4KDRDHODHFLT3 | |
| SCHEMBL29420796 | 0.86 | DHODH (0.40) | EPHX2CYP3A4KDRDHODHFLT3 | |
| SCHEMBL22932335 | 0.84 | EGFR (0.42) | EPHX2DHODHFLT3EGFR | |
| SCHEMBL29420806 | 0.84 | EGFR (0.42) | EPHX2DHODHFLT3EGFR | |
| SCHEMBL22931766 | 0.80 | EPHX2 (0.45) | EPHX2DHODHFLT3 | |
| SCHEMBL24755062 | 0.80 | DHODH (0.40) | EPHX2KDRDHODHFLT3EGFR | |
| SCHEMBL22931770 | 0.78 | FLT3 (0.41) | EPHX2DHODHFLT3EGFR | |
| SCHEMBL22931802 | 0.78 | EPHX2 (0.45) | EPHX2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174291-A | 1,2, 4-oxadiazol-5-one derivatives for the treatment of cancer | 巴斯利尔药物国际股份公司 | 2022-03-11 | — | — | CN | claimed |
| EP-4003983-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica International AG (CH) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174291-A | 1,2, 4-oxadiazol-5-one derivatives for the treatment of cancer | 巴斯利尔药物国际股份公司 | 2022-03-11 | — | — | CN | disclosed |